Close
FINDING CURES TOGETHER<sup>SM</sup>

The 2019 Phillip A. Sharp Awards for Innovation in Collaboration

Resistance to PARP inhibitor plus anti-PD1 therapy driven by ER stress and bioactive lipids in ovarian cancer.

DANDREA_Alan_DAndrea_90x110at96.jpgAlan D'Andrea, MD, Dana-Farber Cancer Institute

Cubillos-Ruiz_Juan_R_90x110at96.2nd.jpgJuan Cubillos-Ruiz, PhD, Weill Cornell Medicine

Grant Term:  June 2019 - May 2021
Total Funding: $250,000

Project Summary
This team will evaluate gene signatures controlled by phospholipid messengers and ER stress in responding and non-responding patients.  It will also utilize tumor organoids to test whether pharmacological inhibition of these pathways can render ovarian tumors susceptible to treatment.

Uncovering mutant TP53 dependencies in spontaneously arising triple-negative breast cancer.

DIBRA_Denada_90x110at72.jpgDenada Dibra, PhD, The University of Texas MD Anderson Cancer Center

LEE_Peter_90x110at72.jpgPeter P. Lee, MD, City of Hope National Medical Center

Grant Term:  May 2019 - April 2020
Total Funding: $250,000

Project Summary
This team will use novel mouse models to study how the TP53 tumor suppressor gene may influence the tumor microenvironment, and to characterize both tumor cells and immune cells that may be present within the tumor tissue.

Non-invasive monitoring of tumor phenotype by interrogation of plasma cell-free RNA.

Maximilian Diehn, MD, PhD, Stanford University School of Medicine

Aaron Hata, MD, PhD, Massachusetts General Hospital Cancer Center

Grant Term: June 2019 - May 2021
Total Funding: $225,000

Project Summary
While circulating tumor DNA (ctDNA) analysis allows non-invasive tumor genotyping, it is unable to assess non-genomic features of tumors such as gene expression. This team seeks to develop a novel method for analyzing cell-free RNA (cfRNA) associated with resistance to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer, to develop a noninvasive approach to better characterize tumors and detect changes in cancer phenotypes during treatment.

Precision combinatorial immunotherapeutic targeting of thymic stromal lymphopoietin receptor (TSLPR) signaling in pediatric and young adult CRLF2-rearranged ALL.

TASIAN_Sarah.jpgSarah Tasian, MD, Children's Hospital of Philadelphia

STEGMAIER_Kimberly_90x110at72.jpgKimberly Stegmaier, MD, Dana-Farber Cancer Institute

Grant Term: June 2019 - May 2021
Total Funding:  $250,000. (This grant was funded with support from the Emily Whitehead Foundation.)

Project Summary
This team will test a novel hypothesis that multi-antigen-specific CAR T cells targeting two or more neoantigens presented by the cancer cells will have superior anti-leukemia efficacy in preclinical models of childhood Down Syndrome-associated ALL and Ph-like ALL, prevent resistance mechanisms observed with single antigen-targeted CAR T cells, and facilitate more durable leukemia remissions in these medically fragile populations.

Antigenicity of mutant KRAS and impact on cancer evolution

VONDERHEIDE_Robert.jpg

Robert H. Vonderheide, MD, DPhil, 
Univ. of Pennsylvania Abramson Cancer Center

BALACHANDRAN_Vinod_90x110at96.jpgVinod P. Balachandran, MD, Memorial Sloan Kettering Cancer Center

Grant Term:  July 2019 - June 2021
Total Funding: $225,000

Project Summary
The team will combine expertise in immunobiology and computational biology to analyze three unique, clinically curated datasets, including short- and long-term pancreatic cancer survivors, primary resected pancreatic cancers, and mKRAS lung and colon cancers, to investigate how mKRAS immunogenicity may dictate outcomes.